Guest Speakers

Dr. Daniel G. Aaron is an Associate Professor of Law at the S.J. Quinney College of Law, University of Utah. He received his JD from Harvard Law School and his MD from the Boston University Chobanian & Avedisian School of Medicine.

Professor Aaron’s research examines how the law shapes life and death in the United States and the legal and social trends that explain the fall in American life expectancy. This involves studying breakdowns in regulatory and legal systems that contribute to American mortality and wrestling with how to repair them. To this end, he has published articles on the intersection of food and drug law, administrative law, tort and multidistrict litigation, tobacco, racial inequity, corporate power, and regulatory capture.

Prior to joining the law school, Professor Aaron clerked for the U.S. Court of Appeals for the Sixth Circuit with Judge John K. Bush. Before that, he served as Assistant Chief Counsel at the U.S. Food and Drug Administration. During that time, he was also a Heyman Fellow at Harvard Law School, and he is a member of the Justice Initiative, a collaboration between Harvard Law School and Howard University School of Law aimed at providing law students a community space to discuss the intersection of race, justice, and the law.

Professor Aaron teaches primarily in the areas of Tort Law and Health Law.

Zachary Baron is a director of the Health Policy and the Law Initiative at the O’Neill Institute for National and Global Health Law and an adjunct professor at Georgetown Law.

For almost 15 years Anna Berent has been entrenched in the field of medical malpractice liability analysis. She’s currently working as a Senior Director of Claims at MCIC Vermont, the largest risk retention group in the country that insures several major hospital systems in the Northeast. Anna’s current role entails leading a team in managing high exposure matters. Having started her career as a litigator, Anna has worked for a premier specialty lines insurance carrier and a medical malpractice third-party administrator. She is a contributor to the ED Management, a monthly Relias publication.

Anna is a graduate of Northeastern University School of Law, and holds an MBA/MS in Healthcare Leadership from Cornell University where she also received her undergraduate degree.

Alexa Berk is Chief Scientific Officer for RWE at CVS Health Clinical Trial Services, where she provides scientific leadership and oversees Data Science for CVS Health CTS. Most recently, Alexa was Medical Affairs Director for Digital Health and Data at Invitae, a leading medical genetics company. Alexa has a history of over 20 years in the health research space including roles at Memorial Sloan Kettering Cancer Center, Novartis Oncology, and top consulting and startup companies focused on RWE. Alexa is a frequent speaker and published author on the topic of high quality real world data and best practices in patient centered research methods, particularly in oncology and rare disease.

Niall Brennan is the Senior Advisor for Data Strategy to the CDC Director. In this role, he provides guidance to the CDC Director on the multi-billion dollar CDC Data Modernization Initiative (DMI), as well as working directly with CDC Centers and Offices to accelerate implementation of the DMI.

Carlos I. Castro has served for over 20 years on Board of Directors of Brazilian large, medium, small public, private, and family-owned companies (SulAmérica, Kepler-Weber, Artecola, Caixacap, Brasilcap), as well as on Board Committees (Corporate, Investment, Financial, Auditing). He served as CEO for twelve years, seven in the financial (savings bonds) and five in the industrial (telecom equipment) industries, as well as in C-Suite positions (CFO, Corporate VP, Pension VP). He led IPOs, strategy, and turnarounds processes. For 20 years he served as a member of the four-member committee in charge of all strategic decisions of the SulAmérica Group. He has extensive exposure to family-owned processes.

For five years, Mr. Castro managed his own consultancy practice, focused on top management issues. He holds a CCA+ certification from IBGC (Brazilian Institute of Corporate Governance), where he is currently a full member of the Healthcare Governance Commission, with a term ending in 2028.

Among many other M&A transactions fully conducted by him, he led the Sul América negotiating teams leading to the business combination with Rede D’Or, creating a joint company valued at over US$ 18 billion (2022), the sale of SulAmérica’s auto insurance business to Allianz (2019), the sale of SulAmérica’s large risk portfolio to AXA, and the JVs with ING (2002) and Aetna (1997). He served on the Ethics Committee of CNSeg for six years, and for seven years as VP of the Brazilian Association of Savings Bonds Companies (Fenacap). For seven years, he acted as an interviewer for the Stanford Graduate School of Business and is currently an interviewer for the Stanford University undergraduate applicants in Rio.

Mr. Castro holds an Electrical Engineering degree from the Catholic University of Rio de Janeiro, Brazil. He is also an MBA and a Master of Sciences in Industrial Engineering (straight “A” student), both degrees from Stanford. He was a Harvard University Research Scholar for the full year of 2019, becoming a Harvard Fellow in the Advanced Leadership Initiative. He has taken several courses in areas such as Sustainability (MIT), Corporate Governance (Stanford), AI (Stanford), Machine Learning and Advanced Analytics in Healthcare (Stanford), Leadership & Innovation (MIT), Electric Vehicles (Stanford), Educational Innovation and Social Entrepreneurship (Harvard), Emerging Technologies in Education (Harvard), and the executive program of Singularity University. Mr. Castro is also experienced in digitalization and ESG processes from a Board of Directors perspective.

Hamza specializes in commercial law, regulatory and governance matters. Hamza has advised on a number of projects with an international focus, including advising clients on inward investment projects into the UK, as well as leading on multi-jurisdictional projects alongside an international team of lawyers.

He has over 12 years’ experience advising clients in the health and social care sector. His key clients include medtech and digital health companies, NHS commissioners and providers, independent operators of health and social care, at-scale providers of primary care services and voluntary sector organizations. He has advised on a broad range of matters, including major strategic procurements, public/private sector collaborations, mergers and acquisitions, regulatory due diligence and highly regulated commercial contracts in the health and social care sector.

Hamza’s experience in advising health and social care sector clients means that he is expert in understanding the regulatory framework that they operate within; his commercial advice is provided in that context.

Relevant experience includes advising:

A range of new market entrants seeking to establish digital health solutions in the NHS on commercial, regulatory and strategic matters.
A national commissioner on the commercial and procurement aspects in a competitive process for a major strategic procurement process to roll out medical technology across the country, focussed on better access to cancer diagnostics.
A medtech company on its contractual arrangements for collaboration with NHS Trusts/FTs for the provision of capital equipment.
Various integrated care systems in the NHS seeking to integrate commissioning governance, and allow for a more co-ordinated provision of health and social care services.

Hamza is recognised by the Legal 500 as a “Next Generation Partner”, and is described as “The ‘quick thinking’ Hamza Drabu who ‘understands clients’ needs and designs creative solutions to complex problems’.”

Hamza featured in the 2,000 Days Project, setting out practical ways to overcome legal barriers in order to help the NHS reform health and social care provision. The 2,000 Days Project was reported on in The Guardian.

Jack Ebeler is a principal at Health Policy Alternatives, a Washington, DC-based consulting firm. In 2009 and 2010, he worked on Capitol Hill on the development of health reform legislation, serving on the staff of the U.S. House of Representatives Committee on Energy and Commerce. Before joining the House Committee staff for the health reform debate, he was an independent consultant and served as a member and then vice-chair of the Medicare Payment Advisory Commission (MedPAC) as it was advancing substantial Medicare payment and delivery reforms. Prior to that, he was president and CEO of the Alliance of Community Health Plans and senior vice president and the initial director of the Health Care Group at the Robert Wood Johnson Foundation. In 1995 and 1996 he served at HHS as deputy assistant secretary for planning and evaluation/health and then as acting assistant secretary for planning and evaluation.

Sabina is Senior Vice President, Business and Technology Services and Chief Information Officer at Abbott. She was promoted to this role in February 2024 after serving as CIO and Vice President, Business & Technology Services. In her current role, Sabina provides executive leadership on technology strategy, policy, and capabilities across the Abbott enterprise.

Sabina joined Abbott in November of 2020 after serving in multiple IT roles at Pfizer, most recently as a Global Head of Upjohn Business Technology, where she was based in Shanghai, China. Prior to joining Pfizer, Sabina held management roles at Arthur Andersen Business Consulting, BearingPoint, and American Express. She is also a former New York City Teaching Fellow where she served as a fifth-grade teacher in the South Bronx.

A diversity and inclusion advocate, Sabina has been actively involved in many aspects of D&I to help build a more diverse workforce and prepare organizations for the years to come, including with organizations such as Advancing Minorities’ Interest in Engineering, which helps prepare underrepresented students for careers in engineering and computer science.

Sabina holds a Bachelor of Science in Commerce with concentrations in Management Information Systems and Finance from the University of Virginia, and a Master of Science in Management and Systems from New York University.

Yvette Fontenot has nearly 25 years of Federal health care experience and has held senior positions on Capitol Hill as well as in the White House and at HHS. She is an expert on the Federal legislative and regulatory process and has long standing relationships with lawmakers, regulators, and thought-leaders. She is currently serving as the Chief Executive Officer of Impact Health Policy Partners.

Judith H. Germano is a nationally-recognized thought leader on cybersecurity governance and privacy issues. She is a Distinguished Fellow at the NYU Center for Cybersecurity (CCS) and Senior Fellow at the Reiss Center on Law and Security, and an Adjunct Professor of Law at NYU School of Law and NYU Stern School of Business. Judi founded the Women Leaders in Cybersecurity series, and leads the CCS Cybersecurity Leaders Roundtable series of corporate executives and senior government officials addressing critical cybersecurity concerns. Judi is a member of the Board of Directors of Dime Community Bancshares Inc. (Nasdaq: DCOM), and serves on the Enterprise Risk, Strategic Planning and Credit Risk committees. Judi also is the founder of GermanoLaw LLC, advising public and privately-held companies and executives on enterprise risk management, cybersecurity and privacy matters, securities fraud and other complex white-collar criminal and regulatory-compliance issues. At GermanoLaw, Judi regularly counsels corporations, senior executives and boards on matters of corporate governance, federal and internal investigations, crisis management, and criminal as well as civil defense.

Judi previously was Chief of Economic Crimes at the US Attorney’s Office for the District of New Jersey. A federal prosecutor for 11 years, Judi supervised and prosecuted complex criminal cases of national and international impact, involving cybercrime, securities and other financial fraud, identity theft, corruption, export enforcement and national security. Judi handled and supervised global cybercrime investigations and prosecuted the District of New Jersey’s first criminal case arising out of evidence obtained pursuant to the Foreign Intelligence Surveillance Act (FISA). Before joining the US Attorney’s Office, Judi worked at the global law firm Shearman & Sterling, and also served as a law clerk to the Honorable Joseph M. McLaughlin of the US Court of Appeals for the Second Circuit, and the Honorable Dominic J. Squatrito of the US District Court for the District of Connecticut.

Judi has a BS from Cornell University, and a JD from St. John’s University School of Law, as a merit scholar. Judi is co-author of two books and has written various whitepapers and articles, including, among others: “Cybersecurity Partnerships: A New Era of Collaboration,” “Third-Party Risk and Corporate Responsibility,” and co-authored “After the Breach: Cybersecurity Liability Risk.”

Mr. Goldberg is an Operating Partner of Arsenal where he focuses on networking and sourcing transactions for the healthcare team. Prior to joining Arsenal in 2014, Mr. Goldberg was a Managing Director, Corporate Development of Endo Pharmaceuticals. Previously, he was a founding Partner of ProQuest Investments and the founding CEO or founder of three biotechnology companies that were acquired or taken public. In addition, he also held executive positions at Becton Dickinson and at GSK. He received his M.B.A. from Harvard Business School and B.A. from Harvard College.

Darryn specialises in information law in the health sector, including data protection, confidentiality and freedom of information.

He has over 7 years’ experience advising clients in the health and care and wider public sectors. His key clients include medtech and digital health companies, NHS commissioners and providers, independent operators of health and social care, higher education institutions and regulators.

Darryn’s experience includes, advising large public and private healthcare organisations on their GDPR-implementation programme, conducting data protection gap analysis exercises, and defending data breach litigation.

He is also regularly instructed in important strategic projects, such as recent patient information sharing arrangements across Berkshire, North Central London, and South East London. In addition, he has previously advised the Information Commissioner on health-sector specific aspects of information and public law.

Relevant experience includes:

Advising the Human Fertilisation and Embryology Authority on complex data protection issues, arising out of transfers of personal data required as a result of a change in service provision.
Defending information law claims brought against public authorities, including data breaches and appeals against Freedom of Information Act decisions (including FOI appeals to the First-tier Tribunal).
Advising on a complex data sharing framework required to support a higher education data analytics provider merger.

Charlotte Ivancic joined Tarplin, Downs & Young, LLC in 2015 as a partner after more than a decade on Capitol Hill serving as a health care policy advisor to members of the United States Senate and United States House of Representatives. She worked for Senator Bill Frist during his time as a Majority Leader, and more recently for Speaker Paul Ryan and Speaker John Boehner. Charlotte was instrumental in developing Speaker Ryan’s Medicare proposals while he was Chairman of the House Budget Committee. Later, she lead the effort to secure passage of historic legislation to repeal Medicare’s sustainable growth rate physician payment formula and replace it with a new payment system that rewards quality. Before working for Congress, Charlotte was a health care attorney in a D.C. regulatory practice. She also worked at Children’s Hospital in Boston prior to attending law school at Boston University, where she concentrated in health law.

Kate is the President of Leone Strategies, and previously served the Staff Director for the U.S. Senate Democratic Steering and Outreach Committee. Prior to that, she was the senior vice president of government relations and a member of the Feeding America executive team. She served as general counsel for U.S. Senator Jeanne Shaheen’s (D-NH) office. Before that, she spent 12 years as the chief health counsel to Senate Democratic Leader Harry Reid (D-NV). During her time with Senator Reid, Kate covered health care for the Leader and served as the lead staffer on health reform and the Affordable Care Act (ACA) — an act she played an instrumental role in shaping and passing in the Senate. Other reform legislation Kate led for Senator Reid includes the Children’s Health Insurance Program Reauthorization Act, the Food and Drug Administration (FDA) Amendments Act, and the FDA Safety and Innovations Act.

Kate has also served as counsel to the previous Senate Democratic Leader, Tom Daschle (D-SD), and worked as a senior policy advisor on the Senate Democratic Policy Committee. Her additional experience includes working on health care matters as an attorney for the U.S. Department of Justice’s Antitrust Division.

Craig Lipset (he/him/his) leads at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures (Perceptive Informatics and Adnexus Therapeutics). During that time, Craig designed and launched multiple industry firsts — from the first fully remote/virtual clinical trial for a new medicine to the first returning of results and data to research participants.

He currently serves on the Board of Directors for the Decentralized Trials & Research Alliance (Co-Chair), Foundation for Sarcoidosis Research and the MedStar Health Research Institute, and, as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig is an Adjunct Assistant Professor in Health Informatics at Rutgers University, and an Adjunct Instructor at the University of Rochester Center for Health + Technology.

Craig has received the red jacket ‘hall of fame’ recognition among the PharmaVOICE most inspiring people in the life sciences. He has been recognized among Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, the Medicine Maker Power List and the AlleyWatch Who’s Who in eHealth. He studied Music at Brandeis University and earned a Master of Public Health from Columbia.

Paul B. Masi is the Executive Director of the Medicare Payment Advisory Commission (MedPAC), a nonpartisan federal commission that advises the U.S. Congress on Medicare payment, quality, and access issues. Prior to his current role at MedPAC, Mr. Masi served as the Unit Chief of the Health Systems and Medicare Cost Estimates Unit at the Congressional Budget Office (CBO), where he led an analytic team in producing baseline projections of Medicare spending, estimating the federal budgetary effects of legislation affecting Medicare, and providing technical assistance on legislation under consideration by the Congress. Mr. Masi previously served as MedPAC’s assistant director, a principal analyst at the CBO, and a research associate at The Urban Institute. He earned an M.P.P. from the University of California at Berkeley and a B.A. in Economics from Davidson College.

Alison has advised clients on product liability and safety issues, especially in the healthcare sector, for over 25 years. She has acted in litigation brought under the Product Liability Directive for a large range of corporate defendants and their insurers.

She acted for the successful defendant in Relph v Yamaha, the first case in the UK under the Consumer Protection Act. She has been instructed by defendants in multi-party pharmaceutical and healthcare product liability litigation, including the coordination of the Hepatitis C group litigation for the National Health Service in A & Others v National Blood Authority. This resulted in the most substantive examination of the European Product Liability Directive to date.

Alison was instructed in respect of the Northwick Park Clinical Trial of TGN1412. She has acted for AstraZeneca in respect of insurance recoveries in the Seroquel litigation and for GSK in the MMR Vaccine litigation.

She has been involved in high profile trans-national litigation, including acting on behalf of Rio Tinto plc in the House of Lords case of Connelly. She has also acted in claims where defendant companies have faced legal challenges on jurisdiction and limitation, including the case of Brooks & Others v The Boots Company PLC.

Aside from litigation, Alison often advises on matters of product safety and regulation as well as product recall.

Alison regularly contributes articles and lectures on product liability law. She read Law at Oxford and Cambridge Universities.

Viraj Narayanan is the Co-CEO of Cornerstone AI, and works alongside founder and co-CEO Michael Elasoff to scale its highly intelligent, automated software platform which has created unparalleled efficiencies while enabling confidence in the fidelity of data needed to answer critical scientific questions.

Prior to joining Cornerstone, Narayanan served as Chief Commercial Officer for Ontada, a McKesson business (NASDAQ: MCK). Under his leadership, they developed first-in-class capabilities to leverage unstructured data and a common data model to create new, higher value recurring products, including the initial commercial sales.

Previously, Narayanan served as the General Manager and Senior Vice President of the life sciences business at COTA, an oncology real-world data and analytics company. He led the scaling of COTA’s life sciences business from the ground up, bridging the gap between stakeholder needs, including the go-to-market strategy for the business unit. Under Narayanan’s leadership, COTA’s real-world data supported sponsors’ regulatory submissions, including an FDA approval in 2021 while achieving double digit growth consistently over 4 years.

Earlier in his career, Narayanan served as a Principal with Decision Strategies International, a Heidrick & Struggles Company (NASDAQ: HSII), as well as a research analyst at Centocor and for the University of Pennsylvania, focusing on natural language processing. He is the author of several thought leadership articles on the role of data in clinical research. Narayanan holds a B.S. in Decision Science from Carnegie Mellon University and an MBA from the Wharton School of Business.

Mindy Nunez Duffourc is an Assistant Professor of Law at Maastricht University in the Netherlands, where she conducts research and teaches as part of the Faculty of Private Law and the Maastricht Law and Tech Lab.

Mindy is also part of the Penn State Dickinson Law research team working on the EU-funded CLASSICA project, Validating AI in classifying cancer in real-time surgery. She researches in the area of comparative health law and technology. Her work has appeared in NPJ Digital Medicine, American Journal of Law and Medicine, Illinois Journal of Law, Technology & Policy, Tulane Journal of International and Comparative Law, Harvard International Law Review Blog, Indiana Health Law Review, and is forthcoming in Springer’s AI, LAW & BEYOND. She was previously an Assistant Professor of Lawyering at NYU and a Lecturer in civil procedure and health law at the University of Passau in Germany. She also served as an Alexander von Humboldt German Chancellor Fellow conducting comparative health law and risk management research and as a Joachim Herz Fellow at Bucerius Law School in Hamburg researching liability for AI in medicine.

Mindy received her J.D. from the University of North Carolina and subsequently practiced law for 12 years as a member of the bar in Illinois and Louisiana. She expects to defend her Ph.D. Dissertation, Liability for Negligent Risk Management in the United States and Germany, at the University of Passau in Summer 2023.

Wendell Primus was the Senior Policy Advisor on Health and Budget issues to Speaker Nancy Pelosi for 18 years. In that capacity, he was the lead House staffer in developing the Affordable Care Act. He also played a major role in the SGR legislation in 2015 and various budget agreements. The drug pricing legislation that was part of the Inflation Reduction Act was his proudest staff accomplishment. He also worked closely with Rep. Karen Bass on the Families First Child Welfare Act.

Prior to this appointment in March 2005, Dr. Primus was the Minority Staff Director at the Joint Economic Committee for two years. He also was Director of Income Security at the Center on Budget and Policy Priorities where much of his work was centered on Unemployment Insurance. He served in the Clinton administration at the Department of Health and Human Services before his resignation. Prior to his appointment at HHS, he was Chief Economist for the House Ways and Means Committee and Staff Director for the Committee’s Subcommittee on Human Resources. At Ways and Means, he worked on the 1983 Social Security Amendments and numerous budget reconciliation bills affecting Medicare in the 1980s. He was also profiled in the New York Times for his work on the 1990 Budget agreement. Dr. Primus received his Ph.D. in economics from Iowa State University.

Rahul is Counselor for International Affairs at the U.S. Treasury Department, where he advises on a range of international financial and economic issues, including the International Monetary Fund and World Bank, G7 and G20, trade and investment, sustainability, and international financial regulation.

Before joining the Biden administration, Rahul was a Managing Director at Lazard in New York where he advised businesses, investors, and governments on a range of financial and strategic matters, including mergers and acquisitions, joint ventures, capital markets, and related issues. His transaction experience spanned the intersection of healthcare, technology, and consumer/retail as well as that of markets and public policy. Rahul founded and led the firm’s special opportunities unit and advised on transactions representing over $200 billion in deal value.

Rahul also directed the Next Bretton Woods Group at the Peterson Institute for International Economics, a global convening forum for rising leaders in economic and financial policy across the G20 economies. Previously, he served as a staff economist for the Council of Economic Advisers at the Obama White House, a consultant for the World Bank, and an advisor to England’s Chief Medical Officer.

Rahul has been named a Truman Scholar, Forbes 30 under 30, Economic Club of New York Fellow, Atlantik-Brücke Young Leader, French-American Foundation Young Leader, BMW Foundation Responsible Leader, Council on Foreign Relations Corporate Leader, and one of Business Insider’s “top dealmakers in digital health,” and he has authored a range of articles, policy briefs, and book chapters on economic issues. He has also served on the board of the Schuyler Center for Analysis and Advocacy and the Lazard Foundation, and was an outside economic advisor for the Biden-Harris presidential campaign.

Rahul received graduate degrees from Oxford and the London School of Economics as a Marshall Scholar, and graduated summa cum laude and Phi Beta Kappa from Rice University with degrees in engineering and economics.

Erin Richardson is Chief of Staff in the Office of the Administrator. Erin joins CMS with a breadth of health policy experience in the federal government, on Capitol Hill, and in the private sector. She most recently held the role of Senior Vice President and Counsel at the Federation of American Hospitals. Prior to that, she served as Senior Policy Advisor at the White House Domestic Policy Council where she focused on Medicare and health information technology policy development and execution.

Manan has decades of US and international health policy, equity, advocacy, public affairs, and communications experience in the pharmaceutical sector. Prior to BMS, Manan was Vice President, and Head of Global Public Affairs for LEO Pharma. Before that, Manan was at Biogen and spent a decade at Novo Nordisk where he first worked in US State government affairs and advocacy, prior to leading the emerging markets region public affairs, based in Zurich, Switzerland. Manan is also an adjunct faculty member at Fairleigh Dickinson University and Rutgers University. He has designed and currently teaches numerous courses including Social & Economic Determinants of Health, Politics & Public Health, Issues in Global Health and Mental Health Advocacy. Manan received his MBA from the University of Illinois-Urbana Champaign, and Master of Public Affairs & Politics from Rutgers University. He did his undergraduate studies at American University. He also has done post-graduate studies at the University of Cambridge, UK, and has a Public Leadership Credential from the Harvard Kennedy School of Government.

Dana is a seasoned advocate and health care policy expert with over 25 years of policy, political, campaign, and legal experience. Prior to Keefe Singiser Partners, Dana served as Senior Vice President for Policy, Campaigns, and Advocacy at Planned Parenthood Federation of America. As a senior member of the staff for over seven years, she was a strategic leader of the organization’s response to the unprecedented attacks on reproductive health care and of the organization’s efforts to protect and expand women’s health care. She worked extensively with Cabinet members, Senators, Members of Congress, senior federal officials, and coalition partners, and appeared frequently in the media.

Corinne leads the national Healthcare Regulatory team advising on all aspects of healthcare law from patient care/consent issues through to statutory powers, governance and assurance. Her health work includes a wide range of areas of advice and reputational management for businesses within the health and social care sector.

Corinne has extensive experience of:

CQC advice including registration, pre and post inspection issues and factual accuracy challenges,
Regulatory due diligence in transactions, vendors and buyers/ funders
Serious clinical incidents
Advocacy in inquests
Risk management
Governance and Assurance
Board development

Corinne is very experienced in offering urgent, pragmatic assistance to healthcare providers where emergency media sensitive matters arise, whether through complaints, regulatory scrutiny, inquests or inquiries.

Her advice work includes assisting both the public and independent health and social care sector on governance, commissioning and consultation. Corinne is well regarded for her wide sector knowledge, helping public and private sector clients steer strategies through the extensive regulatory, legislative and political backdrop in which they operate. She is often called to advise Boards of public and private health and social care providers on assurance on key areas of risk to their corporate health profile, as well as training and developing Boards in engagement on the importance of robust governance and assurance processes.

Vish Srivastava is Co-Founder & CEO of Century Health, an early stage startup applying AI to clinical data to accelerate access to breakthrough treatments. Prior to this he held product leadership roles at Evidation Health, leading the flagship consumer product with over 5 million users, and at BCG Digital Ventures, building new health tech ventures with corporate partners. Vish holds degrees in Design Engineering, Business, and Psychology from Harvard and Michigan, and is based in sunny Los Angeles.

Jannine Versi is the Co-Founder and CEO of Elektra Health, a women’s health company. Elektra provides evidence-based medical care, patient education, and peer support from the menopause transition into the Medicare years. Jannine was previously on the founding team of Cityblock Health, which addresses the medical and social needs of the Medicaid and Dual populations. She has held roles at Google and in the Obama Administration. Jannine earned her BA from the University of Pennsylvania, an MBA from Harvard Business School, and a Fulbright Scholar.

Jeff Wu leads the center’s work promulgating policy and regulations for many of the Affordable Care Act’s health insurance reforms, including the Health Insurance Exchanges, the premium stabilization programs, advance payments of the premium tax credit and cost-sharing reductions, the CO-OP program, regulation of qualified health plans, and eligibility and enrollment standards.

He oversees the center’s communications, stakeholder outreach, and data analysis work, and serves as a member of the center’s senior leadership team. He previously served in various policy positions at CCIIO, as an attorney at the law firm of Covington & Burling LLP, and as a management consultant with Oliver, Wyman & Company. He received an A.B. in economics from Harvard College, a J.D. from Stanford Law School, and an M.B.A. from Stanford Business School.

Mara Youdelman is the Managing Director, Federal Advocacy at the National Health Law Program’s Washington D.C. offices. Mara has worked at the National Health Law Program since 2000 on issues that include Medicaid & CHIP, the Affordable Care Act, language access, and civil rights (including Section 1557 of the Affordable Care Act and demographic data collection). Mara coordinates the National Health Law Program’s federal legislative and administrative work, leading the organization’s efforts at protecting and expanding access to and quality of health care for low-income and underserved populations. Mara also co-chairs The Leadership Conference on Civil and Human Rights’ Health Care Task Force and its Policy & Enforcement Committee.